PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Florbetapir→

Florbetapir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
956103-76-7
Molecular formula
C20H25[18F]N2O3
Molecular weight
359.4 g/mol
Drug class
18F-labelled amyloid beta PET radiotracerdiagnostic imaging agent
Mechanism of action
Binds fibrillar amyloid beta plaques in the brain. PET imaging detects tracer distribution to estimate amyloid pathology; the scan is an adjunct to clinical assessment and not a diagnosis or treatment by itself.
Indications / reported uses
  • PET imaging of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment being evaluated for Alzheimer disease or other causes of cognitive decline

Sources: US DailyMed — AMYVID (florbetapir F18) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Florbetapir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Florbetapir Permitted Daily Exposure (PDE) report (the Florbetapir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Florbetapir Occupational Exposure Limit (OEL) report (the Florbetapir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.